ELCC 2026: Pembrolizumab + Chemo Improves EFS in Early-Stage NSCLC

Martin Reck, MD, PhD, Head of Thoracic Oncology and Head of the Clinical Trial Department, Lung Clinic Grosshansdorf, Germany, presented results from the KEYNOTE-671 trial at the ELCC Congress 2026. The trial compared perioperative pembrolizumab plus chemotherapy with chemotherapy alone in early-stage NSCLC. Five-year follow-up showed improved event-free survival with pembrolizumab, including in patients without a pathological complete response, across all subgroups. Tolerability was consistent with previous reports, with no new safety signals.